APO Research
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drug Conjugate (ADC)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025194 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drug Conjugate (ADC) Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drug Conjugate (ADC) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC) include Arvinas, Bayer Corporation, Bicara Therapeutics, Fabhalta, Immatics, Litfulo, Lytgobi, Merus and Ogsiveo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of First in Class (FIC) Antibody Drug Conjugate (ADC) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents First in Class (FIC) Antibody Drug Conjugate (ADC) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the First in Class (FIC) Antibody Drug Conjugate (ADC) market size, projected growth trends, production technologies, key applications, and end-use industries.

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Company

Arvinas

Bayer Corporation

Bicara Therapeutics

Fabhalta

Immatics

Litfulo

Lytgobi

Merus

Ogsiveo

Pumis Biotechnology (BioNTech)

Regeneron Pharmaceuticals

Skyclary

Talvey

Telix

Truqap

Vertex Pharmaceuticals

AstraZeneca

Dizal Pharma

Shanghai Henlius Biotech, Inc.

GSK

Jiangsu Hengrui Medicine

Pfizer

Akeso, Inc

Lixin Pharmaceutical Technology

Johnson & Johnson

Beijing Hotgen Biotech

Suzhou Yilian Biopharmaceutical

Shenzhen Yipusheng

Foreseen Biotechnology

Suzhou Zejing Biopharmaceutical

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type

Small Molecule FIC Drugs

Large Molecule FIC Drugs

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application

Tumors and Cancers

Others

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drug Conjugate (ADC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drug Conjugate (ADC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the First in Class (FIC) Antibody Drug Conjugate (ADC) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drug Conjugate (ADC) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of First in Class (FIC) Antibody Drug Conjugate (ADC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends Table 2. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers Table 3. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges Table 4. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints Table 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Manufacturers (k units) & (2021-2026) Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Manufacturers Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers, Product Type & Application Table 13. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global First in Class (FIC) Antibody Drug Conjugate (ADC) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Small Molecule FIC Drugs Table 17. Major Manufacturers of Large Molecule FIC Drugs Table 18. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2027-2032) & (k units) Table 21. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2021-2026) Table 22. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2027-2032) Table 23. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2021-2026) & (k units) Table 25. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2027-2032) & (k units) Table 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2021-2026) Table 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Tumors and Cancers Table 29. Major Manufacturers of Others Table 30. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2027-2032) & (k units) Table 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2021-2026) Table 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2027-2032) Table 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2021-2026) & (k units) Table 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2027-2032) & (k units) Table 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2021-2026) Table 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2027-2032) Table 40. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2026) & (k units) Table 42. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2021-2026) Table 43. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecasted Market Share by Region (2027-2032) Table 45. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 47. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 48. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 50. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 57. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region (2021-2026) & (US$ Million) Table 59. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region (2027-2032) & (US$ Million) Table 60. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2021-2026) Table 61. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2027-2032) Table 62. Arvinas Company Information Table 63. Arvinas Business Overview Table 64. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 66. Arvinas Recent Development Table 67. Bayer Corporation Company Information Table 68. Bayer Corporation Business Overview Table 69. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 71. Bayer Corporation Recent Development Table 72. Bicara Therapeutics Company Information Table 73. Bicara Therapeutics Business Overview Table 74. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 76. Bicara Therapeutics Recent Development Table 77. Fabhalta Company Information Table 78. Fabhalta Business Overview Table 79. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 81. Fabhalta Recent Development Table 82. Immatics Company Information Table 83. Immatics Business Overview Table 84. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 86. Immatics Recent Development Table 87. Litfulo Company Information Table 88. Litfulo Business Overview Table 89. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 91. Litfulo Recent Development Table 92. Lytgobi Company Information Table 93. Lytgobi Business Overview Table 94. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 96. Lytgobi Recent Development Table 97. Merus Company Information Table 98. Merus Business Overview Table 99. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 101. Merus Recent Development Table 102. Ogsiveo Company Information Table 103. Ogsiveo Business Overview Table 104. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 106. Ogsiveo Recent Development Table 107. Pumis Biotechnology (BioNTech) Company Information Table 108. Pumis Biotechnology (BioNTech) Business Overview Table 109. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 111. Pumis Biotechnology (BioNTech) Recent Development Table 112. Regeneron Pharmaceuticals Company Information Table 113. Regeneron Pharmaceuticals Business Overview Table 114. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 116. Regeneron Pharmaceuticals Recent Development Table 117. Skyclary Company Information Table 118. Skyclary Business Overview Table 119. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 121. Skyclary Recent Development Table 122. Talvey Company Information Table 123. Talvey Business Overview Table 124. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 126. Talvey Recent Development Table 127. Telix Company Information Table 128. Telix Business Overview Table 129. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 131. Telix Recent Development Table 132. Truqap Company Information Table 133. Truqap Business Overview Table 134. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 136. Truqap Recent Development Table 137. Vertex Pharmaceuticals Company Information Table 138. Vertex Pharmaceuticals Business Overview Table 139. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 141. Vertex Pharmaceuticals Recent Development Table 142. AstraZeneca Company Information Table 143. AstraZeneca Business Overview Table 144. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 146. AstraZeneca Recent Development Table 147. Dizal Pharma Company Information Table 148. Dizal Pharma Business Overview Table 149. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 151. Dizal Pharma Recent Development Table 152. Shanghai Henlius Biotech, Inc. Company Information Table 153. Shanghai Henlius Biotech, Inc. Business Overview Table 154. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 156. Shanghai Henlius Biotech, Inc. Recent Development Table 157. GSK Company Information Table 158. GSK Business Overview Table 159. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 161. GSK Recent Development Table 162. Jiangsu Hengrui Medicine Company Information Table 163. Jiangsu Hengrui Medicine Business Overview Table 164. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 166. Jiangsu Hengrui Medicine Recent Development Table 167. Pfizer Company Information Table 168. Pfizer Business Overview Table 169. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 170. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 171. Pfizer Recent Development Table 172. Akeso, Inc Company Information Table 173. Akeso, Inc Business Overview Table 174. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 175. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 176. Akeso, Inc Recent Development Table 177. Lixin Pharmaceutical Technology Company Information Table 178. Lixin Pharmaceutical Technology Business Overview Table 179. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 180. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 181. Lixin Pharmaceutical Technology Recent Development Table 182. Johnson & Johnson Company Information Table 183. Johnson & Johnson Business Overview Table 184. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 185. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 186. Johnson & Johnson Recent Development Table 187. Beijing Hotgen Biotech Company Information Table 188. Beijing Hotgen Biotech Business Overview Table 189. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 190. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 191. Beijing Hotgen Biotech Recent Development Table 192. Suzhou Yilian Biopharmaceutical Company Information Table 193. Suzhou Yilian Biopharmaceutical Business Overview Table 194. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 195. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 196. Suzhou Yilian Biopharmaceutical Recent Development Table 197. Shenzhen Yipusheng Company Information Table 198. Shenzhen Yipusheng Business Overview Table 199. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 200. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 201. Shenzhen Yipusheng Recent Development Table 202. Foreseen Biotechnology Company Information Table 203. Foreseen Biotechnology Business Overview Table 204. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 205. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 206. Foreseen Biotechnology Recent Development Table 207. Suzhou Zejing Biopharmaceutical Company Information Table 208. Suzhou Zejing Biopharmaceutical Business Overview Table 209. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 210. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 211. Suzhou Zejing Biopharmaceutical Recent Development Table 212. Key Raw Materials Table 213. Raw Materials Key Suppliers Table 214. First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors List Table 215. First in Class (FIC) Antibody Drug Conjugate (ADC) Customers List Table 216. Research Programs/Design for This Report Table 217. Authors List of This Report Table 218. Secondary Sources Table 219. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Image Figure 2. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (2021-2032) & (US$ Million) Figure 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (2021-2032) & (k units) Figure 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Small Molecule FIC Drugs Image Figure 9. Large Molecule FIC Drugs Image Figure 10. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2021-2032) Figure 13. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2021-2032) Figure 16. Tumors and Cancers Image Figure 17. Others Image Figure 18. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2021-2032) Figure 21. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2021-2032) Figure 24. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 26. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 31. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 32. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 38. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 42. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 46. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032) & (US$ Million) Figure 57. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032) & (US$ Million) Figure 59. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. First in Class (FIC) Antibody Drug Conjugate (ADC) Value Chain Figure 65. Manufacturing Cost Structure Figure 66. First in Class (FIC) Antibody Drug Conjugate (ADC) Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule FIC Drugs
  • Large Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Others
Companies covered
  • Arvinas
  • Bayer Corporation
  • Bicara Therapeutics
  • Fabhalta
  • Immatics
  • Litfulo
  • Lytgobi
  • Merus
  • Ogsiveo
  • Pumis Biotechnology (BioNTech)
  • Regeneron Pharmaceuticals
  • Skyclary
  • Talvey
  • Telix
  • Truqap
  • Vertex Pharmaceuticals
  • AstraZeneca
  • Dizal Pharma
  • Shanghai Henlius Biotech, Inc.
  • GSK
  • Jiangsu Hengrui Medicine
  • Pfizer
  • Akeso, Inc
  • Lixin Pharmaceutical Technology
  • Johnson & Johnson
  • Beijing Hotgen Biotech
  • Suzhou Yilian Biopharmaceutical
  • Shenzhen Yipusheng
  • Foreseen Biotechnology
  • Suzhou Zejing Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints
3 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Manufacturers
  1. 3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Manufacturers (2021-2026)
  3. 3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers, Product Type & Application
  7. 3.7 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 First in Class (FIC) Antibody Drug Conjugate (ADC) Tier 1, Tier 2, and Tier 3
4 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Type
  1. 4.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Type Introduction
  2. 4.1.1 Small Molecule FIC Drugs
  3. 4.1.2 Large Molecule FIC Drugs
  4. 4.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type
  5. 4.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2032)
  7. 4.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2021-2032)
  8. 4.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type
  9. 4.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2021-2032)
  11. 4.3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2021-2032)
5 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Application
  1. 5.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Application Introduction
  2. 5.1.1 Tumors and Cancers
  3. 5.1.2 Others
  4. 5.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application
  5. 5.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2032)
  7. 5.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2021-2032)
  8. 5.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application
  9. 5.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2021-2032)
  11. 5.3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2021-2032)
6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
  1. 6.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2032)
  3. 6.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2026)
  4. 6.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region
  1. 7.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region
  2. 7.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region (2021-2026)
  4. 7.1.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region (2027-2032)
  5. 7.1.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032)
  8. 7.2.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032)
  11. 7.3.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Arvinas
  2. 8.1.1 Arvinas Company Information
  3. 8.1.2 Arvinas Business Overview
  4. 8.1.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  6. 8.1.5 Arvinas Recent Developments
  7. 8.2 Bayer Corporation
  8. 8.2.1 Bayer Corporation Company Information
  9. 8.2.2 Bayer Corporation Business Overview
  10. 8.2.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  12. 8.2.5 Bayer Corporation Recent Developments
  13. 8.3 Bicara Therapeutics
  14. 8.3.1 Bicara Therapeutics Company Information
  15. 8.3.2 Bicara Therapeutics Business Overview
  16. 8.3.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  18. 8.3.5 Bicara Therapeutics Recent Developments
  19. 8.4 Fabhalta
  20. 8.4.1 Fabhalta Company Information
  21. 8.4.2 Fabhalta Business Overview
  22. 8.4.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  24. 8.4.5 Fabhalta Recent Developments
  25. 8.5 Immatics
  26. 8.5.1 Immatics Company Information
  27. 8.5.2 Immatics Business Overview
  28. 8.5.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  30. 8.5.5 Immatics Recent Developments
  31. 8.6 Litfulo
  32. 8.6.1 Litfulo Company Information
  33. 8.6.2 Litfulo Business Overview
  34. 8.6.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  36. 8.6.5 Litfulo Recent Developments
  37. 8.7 Lytgobi
  38. 8.7.1 Lytgobi Company Information
  39. 8.7.2 Lytgobi Business Overview
  40. 8.7.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  42. 8.7.5 Lytgobi Recent Developments
  43. 8.8 Merus
  44. 8.8.1 Merus Company Information
  45. 8.8.2 Merus Business Overview
  46. 8.8.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  48. 8.8.5 Merus Recent Developments
  49. 8.9 Ogsiveo
  50. 8.9.1 Ogsiveo Company Information
  51. 8.9.2 Ogsiveo Business Overview
  52. 8.9.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  54. 8.9.5 Ogsiveo Recent Developments
  55. 8.10 Pumis Biotechnology (BioNTech)
  56. 8.10.1 Pumis Biotechnology (BioNTech) Company Information
  57. 8.10.2 Pumis Biotechnology (BioNTech) Business Overview
  58. 8.10.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  60. 8.10.5 Pumis Biotechnology (BioNTech) Recent Developments
  61. 8.11 Regeneron Pharmaceuticals
  62. 8.11.1 Regeneron Pharmaceuticals Company Information
  63. 8.11.2 Regeneron Pharmaceuticals Business Overview
  64. 8.11.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  66. 8.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 8.12 Skyclary
  68. 8.12.1 Skyclary Company Information
  69. 8.12.2 Skyclary Business Overview
  70. 8.12.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  72. 8.12.5 Skyclary Recent Developments
  73. 8.13 Talvey
  74. 8.13.1 Talvey Company Information
  75. 8.13.2 Talvey Business Overview
  76. 8.13.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  78. 8.13.5 Talvey Recent Developments
  79. 8.14 Telix
  80. 8.14.1 Telix Company Information
  81. 8.14.2 Telix Business Overview
  82. 8.14.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  84. 8.14.5 Telix Recent Developments
  85. 8.15 Truqap
  86. 8.15.1 Truqap Company Information
  87. 8.15.2 Truqap Business Overview
  88. 8.15.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  90. 8.15.5 Truqap Recent Developments
  91. 8.16 Vertex Pharmaceuticals
  92. 8.16.1 Vertex Pharmaceuticals Company Information
  93. 8.16.2 Vertex Pharmaceuticals Business Overview
  94. 8.16.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  96. 8.16.5 Vertex Pharmaceuticals Recent Developments
  97. 8.17 AstraZeneca
  98. 8.17.1 AstraZeneca Company Information
  99. 8.17.2 AstraZeneca Business Overview
  100. 8.17.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  102. 8.17.5 AstraZeneca Recent Developments
  103. 8.18 Dizal Pharma
  104. 8.18.1 Dizal Pharma Company Information
  105. 8.18.2 Dizal Pharma Business Overview
  106. 8.18.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  108. 8.18.5 Dizal Pharma Recent Developments
  109. 8.19 Shanghai Henlius Biotech, Inc.
  110. 8.19.1 Shanghai Henlius Biotech, Inc. Company Information
  111. 8.19.2 Shanghai Henlius Biotech, Inc. Business Overview
  112. 8.19.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  114. 8.19.5 Shanghai Henlius Biotech, Inc. Recent Developments
  115. 8.20 GSK
  116. 8.20.1 GSK Company Information
  117. 8.20.2 GSK Business Overview
  118. 8.20.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  120. 8.20.5 GSK Recent Developments
  121. 8.21 Jiangsu Hengrui Medicine
  122. 8.21.1 Jiangsu Hengrui Medicine Company Information
  123. 8.21.2 Jiangsu Hengrui Medicine Business Overview
  124. 8.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  126. 8.21.5 Jiangsu Hengrui Medicine Recent Developments
  127. 8.22 Pfizer
  128. 8.22.1 Pfizer Company Information
  129. 8.22.2 Pfizer Business Overview
  130. 8.22.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  132. 8.22.5 Pfizer Recent Developments
  133. 8.23 Akeso, Inc
  134. 8.23.1 Akeso, Inc Company Information
  135. 8.23.2 Akeso, Inc Business Overview
  136. 8.23.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  138. 8.23.5 Akeso, Inc Recent Developments
  139. 8.24 Lixin Pharmaceutical Technology
  140. 8.24.1 Lixin Pharmaceutical Technology Company Information
  141. 8.24.2 Lixin Pharmaceutical Technology Business Overview
  142. 8.24.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  144. 8.24.5 Lixin Pharmaceutical Technology Recent Developments
  145. 8.25 Johnson & Johnson
  146. 8.25.1 Johnson & Johnson Company Information
  147. 8.25.2 Johnson & Johnson Business Overview
  148. 8.25.3 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  150. 8.25.5 Johnson & Johnson Recent Developments
  151. 8.26 Beijing Hotgen Biotech
  152. 8.26.1 Beijing Hotgen Biotech Company Information
  153. 8.26.2 Beijing Hotgen Biotech Business Overview
  154. 8.26.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  156. 8.26.5 Beijing Hotgen Biotech Recent Developments
  157. 8.27 Suzhou Yilian Biopharmaceutical
  158. 8.27.1 Suzhou Yilian Biopharmaceutical Company Information
  159. 8.27.2 Suzhou Yilian Biopharmaceutical Business Overview
  160. 8.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  162. 8.27.5 Suzhou Yilian Biopharmaceutical Recent Developments
  163. 8.28 Shenzhen Yipusheng
  164. 8.28.1 Shenzhen Yipusheng Company Information
  165. 8.28.2 Shenzhen Yipusheng Business Overview
  166. 8.28.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  168. 8.28.5 Shenzhen Yipusheng Recent Developments
  169. 8.29 Foreseen Biotechnology
  170. 8.29.1 Foreseen Biotechnology Company Information
  171. 8.29.2 Foreseen Biotechnology Business Overview
  172. 8.29.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  174. 8.29.5 Foreseen Biotechnology Recent Developments
  175. 8.30 Suzhou Zejing Biopharmaceutical
  176. 8.30.1 Suzhou Zejing Biopharmaceutical Company Information
  177. 8.30.2 Suzhou Zejing Biopharmaceutical Business Overview
  178. 8.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Price, Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  180. 8.30.5 Suzhou Zejing Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Value Chain Analysis
  2. 9.1.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 First in Class (FIC) Antibody Drug Conjugate (ADC) Production Mode & Process
  6. 9.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors
  9. 9.2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst